Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FTFT NASDAQ:INKT NASDAQ:MDWD NASDAQ:NKTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFTFTFuture FinTech Group$1.23+3.4%$1.32$1.00▼$16.12$7.22M1.8471,380 shs10,172 shsINKTMiNK Therapeutics$11.87+16.6%$10.98$6.80▼$76.00$59.11M0.47194,451 shs128,277 shsMDWDMediWound$14.54+1.4%$16.73$14.14▼$22.50$186.80M0.2196,217 shs191,955 shsNKTXNkarta$3.26+2.0%$2.66$1.63▼$3.65$233.58M0.88797,306 shs133,446 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFTFTFuture FinTech Group-0.83%-1.65%-26.99%-20.67%-78.75%INKTMiNK Therapeutics-2.49%-5.04%-8.62%-7.71%+39.64%MDWDMediWound-14.09%-15.16%-13.52%-18.21%-32.79%NKTXNkarta+4.25%+13.93%+12.72%+21.76%+83.33%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFTFTFuture FinTech Group$1.23+3.4%$1.32$1.00▼$16.12$7.22M1.8471,380 shs10,172 shsINKTMiNK Therapeutics$11.87+16.6%$10.98$6.80▼$76.00$59.11M0.47194,451 shs128,277 shsMDWDMediWound$14.54+1.4%$16.73$14.14▼$22.50$186.80M0.2196,217 shs191,955 shsNKTXNkarta$3.26+2.0%$2.66$1.63▼$3.65$233.58M0.88797,306 shs133,446 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFTFTFuture FinTech Group-0.83%-1.65%-26.99%-20.67%-78.75%INKTMiNK Therapeutics-2.49%-5.04%-8.62%-7.71%+39.64%MDWDMediWound-14.09%-15.16%-13.52%-18.21%-32.79%NKTXNkarta+4.25%+13.93%+12.72%+21.76%+83.33%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFTFTFuture FinTech Group 1.00SellN/AN/AINKTMiNK Therapeutics 2.40Hold$35.00209.76% UpsideMDWDMediWound 2.25Hold$34.00127.18% UpsideNKTXNkarta 2.80Moderate Buy$10.75231.28% UpsideCurrent Analyst Ratings BreakdownLatest INKT, FTFT, NKTX, and MDWD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2026MDWDMediWound HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$36.005/27/2026MDWDMediWound OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$32.005/18/2026NKTXNkarta EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$9.005/18/2026INKTMiNK Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$35.005/18/2026NKTXNkarta EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/13/2026NKTXNkarta Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.005/12/2026INKTMiNK Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/24/2026INKTMiNK Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026MDWDMediWound Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/1/2026INKTMiNK Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$35.003/31/2026NKTXNkarta MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$14.00 ➝ $12.00(Data available from 5/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFTFTFuture FinTech Group$3.50M2.05N/AN/A$7.41 per share0.17INKTMiNK TherapeuticsN/AN/AN/AN/A($2.55) per shareN/AMDWDMediWound$14.48M13.28N/AN/A$3.40 per share4.40NKTXNkartaN/AN/AN/AN/A$4.00 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFTFTFuture FinTech Group-$4.62M-$3.17N/AN/AN/A-37.76%-13.08%-10.33%N/AINKTMiNK Therapeutics-$12.49M-$2.84N/AN/AN/AN/AN/A-118.57%8/13/2026 (Estimated)MDWDMediWound-$23.88M-$2.10N/AN/AN/A-140.80%-65.79%-30.16%8/13/2026 (Estimated)NKTXNkarta-$104.08M-$1.34N/AN/AN/AN/A-30.90%-24.20%8/11/2026 (Estimated)Latest INKT, FTFT, NKTX, and MDWD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/27/2026Q1 2026MDWDMediWound-$0.65-$0.23+$0.42-$0.23$3.37 million$1.48 million5/15/2026Q1 2026FTFTFuture FinTech GroupN/A-$0.25N/A-$0.25N/A$0.21 million5/15/2026Q1 2026INKTMiNK Therapeutics-$0.77-$0.57+$0.20-$0.57N/AN/A5/12/2026Q1 2026NKTXNkarta-$0.39-$0.37+$0.02-$0.37N/AN/A3/25/2026Q4 2025NKTXNkarta-$0.32-$0.37-$0.05-$0.37N/AN/A3/18/2026Q4 2025FTFTFuture FinTech GroupN/A$29.81N/A$2.57N/A$1.35 million3/5/2026Q4 2025MDWDMediWound-$0.65-$0.56+$0.09-$0.56$2.09 million$1.87 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthFTFTFuture FinTech GroupN/AN/AN/AN/AN/AINKTMiNK TherapeuticsN/AN/AN/AN/AN/AMDWDMediWoundN/AN/AN/AN/AN/ANKTXNkartaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFTFTFuture FinTech GroupN/A6.826.82INKTMiNK TherapeuticsN/A1.381.38MDWDMediWoundN/A2.332.17NKTXNkartaN/A12.9612.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFTFTFuture FinTech Group0.19%INKTMiNK Therapeutics2.87%MDWDMediWound46.83%NKTXNkarta80.54%Insider OwnershipCompanyInsider OwnershipFTFTFuture FinTech Group1.50%INKTMiNK Therapeutics22.48%MDWDMediWound9.20%NKTXNkarta8.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFTFTFuture FinTech Group705.87 million5.78 millionNo DataINKTMiNK Therapeutics304.98 million3.86 millionNo DataMDWDMediWound8012.85 million11.67 millionOptionableNKTXNkarta14071.54 million65.54 millionOptionableINKT, FTFT, NKTX, and MDWD HeadlinesRecent News About These CompaniesNkarta, Inc. (NASDAQ:NKTX) Given Consensus Recommendation of "Moderate Buy" by BrokeragesMay 26 at 2:19 AM | americanbankingnews.comNkarta Inc Ordinary Shares NKTXMay 16, 2026 | morningstar.comMHere's Why We're Not Too Worried About Nkarta's (NASDAQ:NKTX) Cash Burn SituationMay 14, 2026 | finance.yahoo.comNkarta Reports First Quarter 2026 Financial Results and Corporate HighlightsMay 12, 2026 | globenewswire.comNkarta (NKTX) Projected to Post Earnings on WednesdayMay 6, 2026 | marketbeat.comNkarta, Inc. (NASDAQ:NKTX) Given Average Rating of "Hold" by AnalystsMay 1, 2026 | marketbeat.comNkarta (NASDAQ:NKTX) Stock Price Down 3.1% - Here's WhyApril 28, 2026 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Nkarta (NKTX), QT Imaging Holdings (QTI) and Cardiff Oncology (CRDF)April 23, 2026 | theglobeandmail.comNKTX Stock Up on Upbeat Regulatory Update on Lead Autoimmune ProgramApril 17, 2026 | zacks.comNkarta rises on FDA agreement for amended trial protocolApril 16, 2026 | msn.comNkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology CentersApril 15, 2026 | globenewswire.comNkarta to Participate in Needham Virtual Healthcare ConferenceApril 9, 2026 | globenewswire.comNkarta Launches $100 Million At-the-Market Stock OfferingMarch 26, 2026 | tipranks.comNkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate HighlightsMarch 25, 2026 | globenewswire.comNkarta to Participate in March Investor ConferencesFebruary 27, 2026 | globenewswire.comInsider Selling: Nkarta (NASDAQ:NKTX) President Sells 5,649 Shares of StockJanuary 21, 2026 | insidertrades.comWe Think Nkarta (NASDAQ:NKTX) Needs To Drive Business Growth CarefullyDecember 4, 2025 | finance.yahoo.comNkarta to Participate in Evercore Healthcare ConferenceDecember 2, 2025 | globenewswire.comNkarta: Pushing Deeper And Deeper Into A Discount Vs. Their Holdings, For No Real ReasonNovember 22, 2025 | seekingalpha.comAnalysts Offer Insights on Healthcare Companies: Rallybio (RLYB) and Nkarta (NKTX)November 11, 2025 | theglobeandmail.comNkarta price target lowered to $11 from $12 at StifelNovember 11, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeINKT, FTFT, NKTX, and MDWD Company DescriptionsFuture FinTech Group NASDAQ:FTFT$1.23 +0.04 (+3.36%) As of 01:14 PM EasternFuture FinTech Group Inc., through its subsidiaries, operates online shopping platforms in People's Republic of China. It operates in three segments: Supply Chain Financing Service and Trading Business, Asset Management Service, and Others. The company offers cross-border money transfer service, brokerage and investment banking, and cryptocurrency mining farm business. It also engages in the trading of coal, aluminum ingots, sand, and steel; and E-commerce, digital wallet safety management, blockchain code auditing and operations, cryptocurrency mining, metaverse and big data maintenance services. The company was formerly known as SkyPeople Fruit Juice, Inc. and changed its name to Future FinTech Group Inc. in June 2017. Future FinTech Group Inc. is headquartered in New York, New York.MiNK Therapeutics NASDAQ:INKT$11.86 +1.69 (+16.55%) As of 02:01 PM Eastern This is a fair market value price provided by Massive. Learn more.MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.MediWound NASDAQ:MDWD$14.54 +0.21 (+1.43%) As of 02:01 PM Eastern This is a fair market value price provided by Massive. Learn more.MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.Nkarta NASDAQ:NKTX$3.26 +0.07 (+2.04%) As of 02:01 PM Eastern This is a fair market value price provided by Massive. Learn more.Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas IREN Is Flipping the Switch from Bitcoin to AI This Quantum Computing Stock May Be Closer to a Breakout Than You Think Microsoft Is Spending Billions on AI, But Investors Aren’t Buying It If the Market Rally Stalls, This ETF Can Insulate Portfolios RTX Is Set to Revolutionize Munitions Manufacturing Is Co-Diagnostics National Security’s Next Diagnostic Pick? Semtech’s Explosive Rally May Only Be Getting Started The Food Delivery War Just Entered Its Final Phase Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
